PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer | The NEW ENGLAND JOURNAL Of MEDICINE

Authors: Andrea Cercek, M.D., Melissa Lumish, M.D. https://orcid.org/0000-0003-4173-5567, Jenna Sinopoli, N.P., Jill Weiss, B.A., Jinru Shia, M.D., MichelleLamendola-Essel, D.H.Sc., Imane H. El Dika, M.D., and Luis A. Diaz, Jr., M.D.

BACKGROUND

Neoadjuvant chemotherapy and radiation followed by surgical resection of the rectum is a standard treatment for locally advanced rectal cancer. A subset of rectal cancer is caused by a deficiency in mismatch repair. Because mismatch repair–deficient colorectal cancer is responsive to programmed death 1 (PD-1) blockade in the context of metastatic disease, it was hypothesized that checkpoint blockade could be effective in patients with mismatch repair–deficient, locally advanced rectal cancer.

METHODS

We initiated a prospective phase 2 study in which single-agent dostarlimab, an anti–PD-1 monoclonal antibody, was administered every 3 weeks for 6 months in patients with mismatch repair–deficient stage II or III rectal adenocarcinoma. This treatment was to be followed by standard chemoradiotherapy and surgery. Patients who had a clinical complete response after completion of dostarlimab therapy would proceed without chemoradiotherapy and surgery. The primary end points are sustained clinical complete response 12 months after completion of dostarlimab therapy or pathological complete response after completion of dostarlimab therapy with or without chemoradiotherapy and overall response to neoadjuvant dostarlimab therapy with or without chemoradiotherapy.
PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer

RESULTS

A total of 12 patients have completed treatment with dostarlimab and have undergone at least 6 months of follow-up. All 12 patients (100%; 95% confidence interval, 74 to 100) had a clinical complete response, with no evidence of tumor on magnetic resonance imaging, 18F-fluorodeoxyglucose–positron-emission tomography, endoscopic evaluation, digital rectal examination, or biopsy. At the time of this report, no patients had received chemoradiotherapy or undergone surgery, and no cases of progression or recurrence had been reported during follow-up (range, 6 to 25 months). No adverse events of grade 3 or higher have been reported.

CONCLUSIONS

Mismatch repair–deficient, locally advanced rectal cancer was highly sensitive to single-agent PD-1 blockade. Longer follow-up is needed to assess the duration of response. (Funded by the Simon and Eve Colin Foundation and others; ClinicalTrials.gov number, NCT04165772.)
Locally advanced rectal cancer is typically managed with multimodal therapy, including chemotherapy, radiation, and surgery. Current evidence supports a strategy involving the use of neoadjuvant therapy, in which induction chemotherapy with a fluoropyrimidine in combination with oxaliplatin is followed by chemoradiotherapy and then surgery.1-3 This approach results in a pathological complete response in up to a quarter of patients, but it is associated with marked complications and toxic effects — including bowel, urinary, and sexual dysfunction; infertility; and altered quality of life — in a substantial proportion of patients.4-6 In patients undergoing surgery, resection of the rectum is life-altering and often warrants a permanent diverting colostomy.6,7 Owing to the complications of surgery and the high frequency of pathological complete response, interest in organ-sparing nonoperative management is increasing. The use of clinical complete response that is achieved with neoadjuvant treatment as a surrogate for pathological complete response provides patients with a nonoperative option that results in a survival benefit that is similar to that in patients undergoing surgical resection.8-11
Approximately 5 to 10% of rectal adenocarcinomas are mismatch-repair deficient, and these tumors have been shown to respond poorly to standard chemotherapy regimens, including neoadjuvant chemotherapy in locally advanced rectal cancer.12-14 Immune checkpoint blockade alone has been shown to be highly effective as first-line treatment for patients with mismatch repair–deficient metastatic colorectal cancer, as well as for patients with treatment-refractory disease, with objective response rates of 33 to 55%, clinically significant durability of response, and prolonged overall survival.15-17
On the basis of the benefits seen in the context of metastatic disease, we hypothesized that single-agent programmed death 1 (PD-1) blockade alone might be beneficial in mismatch repair–deficient, locally advanced rectal cancer. To test this hypothesis, we initiated a phase 2 study to investigate the overall response and frequency of sustained clinical complete response to neoadjuvant treatment with dostarlimab, a PD-1 inhibitor, in this patient population.

Skip The Scoop | Seek Understanding

Biden twiddles his thumbs as kidnapped journalist is tortured in Belarus

Show Me

Soros Backed Sheriff Penzone and the Maricopa County Board Wouldn’t Turn Over Router Data to AZ Senate Audit – He’s Now Likely Facing Contempt Charges In Another Case

Show Me

Establishment Media Float Another Anti-Trump Conspiracy Theory: ‘Backwards’ Pants Means ‘Dementia’

Show Me

Hypocrisy & Gaslighting 101 | “Twitter declares access to its platform a ‘human right’ despite banning Trump”

Show Me

Nigeria Suspends Twitter Days After President’s Post Removed

Show Me

President Trump Makes A Comeback Speech In North Carolina

Show Me

‘The Bigotry Of Low Expectations’: Horace Cooper Dismisses Biden’s Claim That Black People Can’t Hire Lawyers, Accountants

Show Me

New York Mayoral Candidate, Now Claiming to Be Pro-Trump, Bashed Him as ‘Arrogant’ and Praised Mass Amnesty

Show Me

Governor Newsom Reneges on Promise to Surrender His Emergency COVID-19 Powers

Show Me

Hawaii to drop quarantine, COVID-19 testing once 70% of state is vaxxed

Show Me

SARAH VINE: This war on mothers is feminism’s biggest fight for decades 

Show Me

Over 138,000 Americans Tune in to Watch President Trump’s NC Speech… Before He Even Takes the Stage — Joe Biden Is LUCKY to Get 1,000

Show Me

Dr. Nicole Saphier on Gain of Function Research in Wuhan Lab, Fauci’s Emails, and the Politicization of COVID-19

Show Me

If You Think Intimidation Will Stop, Think Again. The ‘Left’ Doubles Down | “Cancel Culture Works. We Wouldn’t Have Marriage Equality Without It.”

Show Me

Joe Biden Just Banned Investment In CCP Military Firms His Son Hunter Profited From.

Show Me

U.S. Hits 300 Million Doses With Covid in Retreat: Virus Update

Show Me

Britain will lead the way on vaccine passports at the G7 summit

Show Me

Bannon’s War Room | Saturday Edition Hour 1 | Recorded June 5, 2021 | Video: 48 Minutes 38 Seconds

Show Me

Bannon’s War Room | Saturday Edition Hour 2 | Recorded June 5, 2021 | Video: 48 Minutes 38 Seconds

Show Me

Common Sense In A Senseless World | Thomas Sowell Full Documentary | Video: 56 Minutes 57 Seconds

Show Me

BOOM! Mike Lindell Files Fed Lawsuit Against Dominion and Smartmatic For “Weaponizing the court system” To SILENCE Lindell And Others About Election Fraud

Show Me

June 4, 2021 | Nightly News Rebroadcast | Video: 49 Minutes 53 Seconds

Show Me

Clean Elections Court Victory!

Show Me

COVID Origin ‘Worst Cover-Up in Human History’ + More

Show Me

BOMBSHELL: Fauci Kept Funding Peter Daszak’s Wuhan ‘Gain of Function’ Experiments with $7.5 Million after Trump Canceled Grant

Show Me

Iran’s Proxies in Iraq Threaten U.S. With More Sophisticated Weapons

Show Me

The Great Thomas Sowell | John Stossel Retrospective

Show Me

Bannon’s War Room | Morning Edition Hour 1 | Recorded June 4, 2021 | Video: 48 Minutes 28 Seconds

Show Me

Bannon’s War Room | Morning Edition Hour 2 | Recorded June 4, 2021 | Video: 47 Minutes 49 Seconds

Show Me

Bannon’s War Room | Evening Edition | Recorded June 4, 2021 | Video: 47 Minutes 49 Seconds

Show Me

June 3, 2021 | Nightly News Rebroadcast | Video: 54 Minutes 38 Seconds

Show Me

Govt. violates law; stalls Freedom of Info requests for specific Covid-19 Fauci emails

Show Me

Of Course | “Google Diversity Chief Will Remain at Company in Wake of Anti-Semitic Remarks”

Show Me

Media Ignores Heinous Attack on Republican Lawmaker’s Home

Show Me

Justice Department investigating law firm linked to Hunter Biden’s Burisma work

Show Me

NASA aims for 2 new missions to Venus to learn about ‘lost habitable’ world

Show Me

A New York 7-Year-Old Was Accused of Rape. Is Arresting Him the Answer?

Show Me

Trump Admin Covertly Obtained Phone Records Of NYT Reporters

Show Me

Vet’s mic cut off as he spoke of role freed slaves played in Memorial Day origins

Show Me

Rand Paul Doubles Down on #FauciEmails, Calls Fauci ‘Morally Culpable’ for Pandemic

Show Me